1.
Schreiber R, Lewis C, Crane K. Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. J of Skin [Internet]. 2018Dec.17 [cited 2022Jul.5];2:S57. Available from: https://www.jofskin.org/index.php/skin/article/view/455